and Pfizer Inc., both of New York, announced topline results of the Phase III ARISTOTLE trial of Eliquis (apixaban) for treatment of patients with atrial fibrillation and at least one additional risk factor for stroke, that showed Eliquis met the primary efficacy objective of noninferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism

The trial of 330 patients will evaluate overall survival with vaccination by IMA901 in combination with sunitinib (Sutent, Pfizer Inc.), in a general population of patients and in a subpopulation of patients positive for a biomarker signature associated with improved clinical outcome

NovaDel Pharma Inc., of Bridgewater, N.J., opened an investigational new drug application with the FDA for Duromist, an oral spray formulation of New York-based Pfizer Inc.'s Viagra (sildenafil) for erectile dysfunction

BioSpecifics Technologies Corp., of Lynbrook, N.Y., said Pfizer Inc., of New York, reported data showing no statistically meaningful differences between hands that had undergone previous surgery for Dupuytren's contracture vs...The trial is expected to test the drug against Celebrex (celecoxib, Pfizer Inc.), and anti-arthritic efficacy will be evaluated using the standardized Western Ontario and McMaster Universities OA Index and its subscales for pain, stiffness and physical function

Amgen Inc., of Thousand Oaks, Calif., and Pfizer Inc., of New York, reported results from several studies of Enbrel (etanercept) at the European League Against Rheumatism meeting in London and at the World Congress of Dermatology meeting in Seoul, South Korea...Pfizer Inc., of New York, presented full data from its ORAL Sync trial of tofacitinb, an oral JAK inhibitor, which met its endpoint earlier this year, at the European League Against Rheumatism meeting in London

The Phase II study will compare THVD-201 to placebo and Detrol (tolterodine, Pfizer Inc

Pfizer Inc., of New York, announced top-line results from the ORAL Standard and ORAL Step Phase III rheumatoid arthritis (RA) studies of tofacitinib

Pfizer Inc., of New York, reported top-line data from its ORAL Scan Phase III study of JAK inhibitor tofacitinib (formerly tasocitinib), showing that the drug met all primary endpoints and showed statistically significant changes vs

Pfizer Inc., of New York, reported data from an open-label extension study of its pivotal Phase II/III trial of tafamidis for transthyretin familial amyloid polyneuropathy that showed slowing of disease progression sustained for 30 months

Eladur is partnered with King Pharmaceuticals Inc., now owned by New York-based Pfizer Inc

Lpath Inc., of San Diego, began enrollment in a Phase Ib/IIa trial of iSONEP, an ocular drug candidate partnered with New York-based Pfizer Inc

PF-04523655 incorporates Silence's AtuRNAi technology and was sublicensed to New York-based Pfizer Inc

The study is part of a 2009 collaboration between Athersys and New York-based Pfizer Inc

Pfizer Inc., of New York, reported that the second Phase III study of oral JAK inhibitor tofacitinib (formerly tasocitinib) met the primary endpoints by showing statistically significant changes vs

Amgen Inc., of Thousand Oaks, Calif., and Pfizer Inc., of New York, said results from a Phase IV trial showing that Enbrel (etanercept) significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis compared to placebo

Inspiration Pharmaceuticals Inc., of Laguna Niguel, Calif., said results from the Phase I portion of an ongoing IB1001 study demonstrated noninferiority of the drug in achieving overall levels of replacement factor compared to BeneFIX, an approved recombinant FIX product for hemophilia B marketed by New York-based Pfizer Inc

Icagen Inc., of Research Triangle Park, N.C., and partner Pfizer Inc., of New York, started dosing healthy volunteers in a Phase I trial of a subtype-selective Nav1 .7 compound under the firms' sodium channel collaboration

Medivation Inc., of San Francisco, completed enrollment in its Phase III CONCERT trial evaluating dimebon plus Aricept (donepezil, Pfizer Inc.) in mild-to-moderate Alzheimer's disease

Top-line data showed that PT003 provided superior bronchodilation compared to current market lead Spiriva (tiotropium bromide, Pfizer Inc.), as well as to Foradil (formoterol fumarate, Novartis AG), placebo and the individual components of PT003 (p is less than or equal to 0.0002 for all comparisons